Actively Recruiting
Refractory Breathlessness in COPD
Led by Seoul National University · Updated on 2025-09-08
730
Participants Needed
1
Research Sites
402 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to investigate the prognosis and clinical outcomes of patients with chronic obstructive pulmonary disease (COPD) who continue to experience refractory dyspnea despite treatment with long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA). The research will prospectively follow a cohort of patients to identify clinical factors, lung function parameters, imaging features, and cardiovascular indicators associated with poor treatment response. By comparing these patients with those who show symptom improvement, the study seeks to determine predictors of exacerbations, lung function decline, and mortality. Findings are expected to guide the development of targeted strategies to improve the management of refractory dyspnea in COPD.
CONDITIONS
Official Title
Refractory Breathlessness in COPD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults (18 years or older) diagnosed with COPD according to GOLD 2025 criteria
- Presence of COPD risk factors such as smoking history, occupational exposure, or genetic predisposition
- Typical symptoms including breathlessness, cough, or sputum production
- Post-bronchodilator FEV1/FVC ratio less than 0.70
- Regular follow-up at a respiratory outpatient clinic
- Received LABA/LAMA combination therapy for at least 3 months before enrollment
- Ability and willingness to provide written informed consent
You will not qualify if you...
- Poor adherence to LABA/LAMA therapy (medication possession rate below 50%) or refusal of treatment
- Inability or unwillingness to attend scheduled visits, tests, or follow-up procedures
- Severe comorbid conditions expected to greatly affect prognosis, including end-stage diseases with life expectancy under 1 year
- Terminal cancers receiving hospice or palliative care
- Any condition that may interfere with study participation or data accuracy, as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Seoul National University College of Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center
Seoul, Seoul, South Korea, 07061
Actively Recruiting
Research Team
H
Hyun Woo Lee, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here